Cell/Gene Tx channel feed

Au­toim­mune pa­tients in CAR-T study see strik­ing im­prove­ments across lu­pus and oth­er dis­eases

22 hours ago
R&D

Roche part­ner touts ear­ly al­lo­gene­ic CAR-T da­ta at #ASH23, but dura­bil­i­ty re­mains key ques­tion

23 hours ago
R&D

Ar­cel­lx, Kite aim to keep chip­ping away at Carvyk­ti ad­van­tage with new mul­ti­ple myelo­ma da­ta: #ASH23

Yesterday
R&D

As cash runs tight, blue­bird plunges af­ter pric­ing sick­le cell gene ther­a­py well above com­peti­tor and fail­ing to win re­view vouch­er

2 days ago
Pharma

How one lab's decades­long search for the 'holy grail' of sick­le cell led to the first CRISPR ther­a­py

3 days ago
R&D
In Focus

Af­ter ink­ing re­verse merg­er, Graphite Bio di­vests gene edit­ing pipeline to new­ly-formed biotech

3 days ago
Startups
R&D

Cel­lec­tis shifts CAR-T man­u­fac­tur­ing in-house, boosts ef­fi­ca­cy com­pared to third-par­ty CD­MOs: #ASH23 

3 days ago
Manufacturing

Sen. Bill Cas­sidy plots a path for more com­mer­cial­ly vi­able cell and gene ther­a­pies

5 days ago
Pharma

A CAR-T ther­a­py in­vent­ed at Seat­tle Chil­dren’s was nev­er ap­proved for kids. Now the hos­pi­tal is launch­ing its own pe­di­atric CAR-T start­up

6 days ago
Startups

CRISPR repri­or­i­tizes CAR-T pipeline with cuts, ex­pands in­to au­toim­mune dis­ease as US de­ci­sion for exa-cel looms

6 days ago
R&D

At­se­na touts one-year da­ta for con­gen­i­tal eye dis­ease ther­a­py as it seeks part­ner for piv­otal study

Last week
R&D

Or­na Ther­a­peu­tics trims staff in ‘de­fen­sive re­duc­tion’ de­spite large fi­nanc­ing hauls

Last week
People
Startups

Clin­i­cians say ben­e­fits of CAR-T con­tin­ue to out­weigh risk of T-cell ma­lig­nan­cies

Last week
Pharma
FDA+

Gilead­'s cell ther­a­py busi­ness Kite cuts 7% of work­force

Last week
People

Gen­er­a­tion Bio to lay off 68 em­ploy­ees in a dif­fi­cult year for non-vi­ral gene ther­a­py biotechs

Last week
People

FDA opens re­view of CAR-T safe­ty af­ter iden­ti­fy­ing 19 cas­es of post-treat­ment blood can­cer

Last week
Pharma
FDA+

Bio­Marin lands three-year deal for Ger­man cov­er­age of gene ther­a­py at $900K per pa­tient

Last week
Pharma

RoslinCT to com­mer­cial­ly man­u­fac­ture CRISPR-edit­ed ther­a­py Cas­gevy af­ter col­lab ex­ten­sion with Ver­tex, CRISPR

Last week
Manufacturing

Marks: FDA open to us­ing sin­gle-arm stud­ies for ac­cel­er­at­ed ap­proval of rare dis­ease gene ther­a­pies

Last week
FDA+

Feng Zhang's lat­est gene edit­ing trawl reels in 188 new CRISPR sys­tems

2 weeks ago
R&D
Discovery

CAR-T cell ther­a­pies in­fused in­to brain shrink tu­mors in two glioblas­toma stud­ies

3 weeks ago
R&D

Bris­tol My­ers and 2sev­en­ty bio say FDA de­layed CAR-T ther­a­py de­ci­sion

3 weeks ago
FDA+

Astel­las de­tails po­ten­tial rea­son be­hind deaths in rare dis­ease gene ther­a­py tri­al

4 weeks ago
R&D

Pa­tient foun­da­tion ac­cus­es rare dis­ease com­pa­ny Taysha of vi­o­lat­ing li­cens­ing agree­ment

4 weeks ago
R&D
1234 Next page Last page
A service from the Financial Times